Publications by authors named "Leonardo R Silva"
Background: Breast cancer outcomes among patients who use safety-net hospitals in the highly populated Harris County, Texas and Southeast Brazil are poor. It is unknown whether treatment delay contributes to these outcomes.
Methods: We conducted a retrospective cohort analysis of patients with non-metastatic breast cancer diagnosed between January 1, 2009 and December 31, 2011 at Harris Health Texas and Unicamp's Women's Hospital, Barretos Hospital, and Brazilian National Institute of Cancer, Brazil.
Male breast cancer (MBC) is now considered molecularly different from female breast cancer (FBC). Evidence from studies indicates that common genetic and epigenetic features of FBC are not shared with those diagnosed in men. Genetic predisposition is likely to play a significant role in the tumorigenesis of this rare disease.
View Article and Find Full Text PDFArticle Synopsis
- Neoadjuvant endocrine therapy (NET) has shown effectiveness in treating ER-positive/HER2-negative breast cancer in clinical trials, but its real-world adoption remains low; this study aimed to provide insights from actual practice.
- A cohort of 146 postmenopausal women undergoing NET was evaluated, with findings indicating a median age of 67 and a majority having early-stage disease, treated predominantly with aromatase inhibitors for about 21 weeks without any tumor progression.
- The study found that NET is both effective and safe, suggesting that factors like postmenopausal status and low-risk tumor characteristics should be considered when selecting patients for this therapy.
Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy.
Front Oncol
April 2020
Mutations in the gene (m) are important mechanisms of resistance to endocrine therapy in estrogen receptor-positive (ER+) metastatic breast cancer and have been studied as a potential therapeutic target, as well as a predictive and prognostic biomarker. Nonetheless, the role of m as a possible mechanism of primary endocrine resistance, as well as whether it also occurs in tumors that are resistant to ET administered in early-stage disease as (neo)adjuvant, has not been adequately studied. In this study, we evaluated the prevalence of m in tumor samples from patients with ER+ breast cancer resistant to neoadjuvant aromatase inhibitor therapy.
View Article and Find Full Text PDFAssociation of Menopausal Status, Expression of Progesterone Receptor and Ki67 to the Clinical Response to Neoadjuvant Chemotherapy in Luminal Breast Cancer.
Rev Bras Ginecol Obstet
December 2019
Objective: To identify the biomarkers of response to neoadjuvant chemotherapy in early luminal breast cancer.
Methods: A cross-sectional study that included all patients with early or locally-advanced luminal breast cancer submitted to neoadjuvant chemotherapy between 2013 and 2014. Demographic, clinic and pathologic data were retrieved from patient records.
Skeletal muscle metaboreflex in patients with chronic renal failure.
Clin Physiol Funct Imaging
March 2017
The sympathetic nervous system is affected in patients with chronic renal failure (CRF). This study tested the hypothesis that patients with CRF have an altered skeletal muscle metaboreflex. Twenty patients with CRF and 18 healthy subjects of similar age participated in the study.
View Article and Find Full Text PDF